Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 1,640 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sexual Activity Clear all

Conditions: Erectile Dysfunction, Prostate Cancer
Interventions: Tacrolimus, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Up to 65 Years · Male only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York • Cleveland, Ohio + 2 more

Conditions: Alcohol Use, Unspecified, Substance Use, Sex Behavior
Interventions: PrEP acronym (pre-exposure prophylaxis), Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Smoking Cessation
Interventions: Nicotine transdermal patch; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 23 Years to 60 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Female Patients With High Tone Pelvic Floor Dysfunction
Interventions: Vaginal Diazepam Suppository, Placebo Suppository; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections, HIV Seronegativity
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • Honolulu, Hawaii + 5 more

Conditions: HIV/AIDS
Interventions: Infectiousness Risk Reduction, General Health Improvement; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: LEXIVA (GW433908), Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more

Conditions: HIV Infections, Hyperlipidemia, Exercise
Interventions: l-carnitine; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: HIV
Interventions: Community Events, Social Network HIV Testing, Peer Network Intervention; Behavioral
Lead sponsor: City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 3,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 141
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 3,526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intravaginal Ring Use
Interventions: Not listed
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Rectal Cancer, Rectum
Interventions: questionnaires, CSI-SH- Cancer Survivorship Intervention; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Chlamydia
Interventions: Project Connect; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 11 Years to 20 Years
Enrollment: 36,502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Early-phase Safety and PK Study of a Vaginal Gel
Interventions: YASO GEL, Placebo gel; Drug
Lead sponsor: Yaso Therapeutics Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Coitus
Interventions: Intimate Health Gel; Other
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: West Palm Beach, Florida • Beachwood, Ohio

Conditions: HIV/AIDS, Substance Use, Bisexuality
Interventions: HIV and substance use prevention; Behavioral
Lead sponsor: Rosalind Franklin University of Medicine and Science; Other
Eligibility: 14 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Infertility, Pregnancy
Interventions: Crinone vaginal progesterone gel, Placebo vaginal gel; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: PRP, Sexual Function Disturbances, Genitourinary Syndrome of Menopause, Postmenopausal Symptoms, Vaginal Atrophy
Interventions: Injection of platelet-rich plasma, Injection of saline; Procedure
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Vaginal Laxity, Urinary Incontinence, Sexual Dysfunction
Interventions: Intragen fractional radiofrequency with NeuViVa; Device
Lead sponsor: SHERRY Thomas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Agoura Hills, California

Conditions: Erectile Dysfunction
Interventions: Platelet rich plasma, Placebo Sham Injection; Biological · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: COBI, DRV, NRTIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 48
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more

Search by objective public record fields.

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

ANCHORS Alcohol & Sexual Health Study: UH3 Project

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Smoking Cessation and Sexual Health in Men

Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.

A Study of Immune System Activity in Healthy Adults

Behavioral Intervention to Enhance HIV Test/Treat

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART

Adaptation and Implementation of Project Encuentro in the U.S.-Mexico Border

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Women's Input on Sexual Health

The Sexual Health of Rectal Cancer Patients

Multi-level Interventions for STD Prevention Among Adolescents

FIH Lead-in Study of YASO GEL Followed by a Phase 1 Randomized, Double-blind Study to Assess Safety and Pharmacokinetics of YASO GEL

In-Home Use Study to Evaluate Use of an Intimate Health Product in Females

Understanding and Reducing HIV Risk Behavior and Substance Use Among Self-identified Bisexual Adolescent Men

Sexual Absorption of Vaginal Progesterone

PRP Injections for Genitourinary Syndrome of Menopause

Evaluation Using Intragen Fractional Radiofrequency With NeuViVa for the Treatment of Vaginal Laxity and Urogynecology Symptoms.

The Role of Platelet Rich Plasma for Erectile Dysfunction

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults